Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8323021 | 0.82 | ALDH1A1 (0.47) | LMNACYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13971307 | 0.81 | CSNK1A1 (0.46) | LMNAHTTCYP3A4SMN1; SMN2CYP2D6 | |
| SCHEMBL7908992 | 0.81 | GSTO1 (0.45) | LMNACYP3A4SMN1; SMN2MEN1CYP2D6 | |
| SCHEMBL5700130 | 0.79 | CYP17A1 (0.42) | LMNACYP3A4SMN1; SMN2CA12CA1 | |
| SCHEMBL30014015 | 0.78 | FTO (0.46) | LMNAHTTCYP3A4SMN1; SMN2CYP2D6 | |
| SCHEMBL6618815 | 0.78 | CA12 (0.47) | LMNAHTTCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL18230 | 0.76 | CA12 (0.41) | LMNACA12CA1CA2CA9 | |
| SCHEMBL8563450 | 0.76 | ALDH1A1 (0.57) | LMNAMEN1KMT2ATP53MAPT | |
| SCHEMBL30727320 | 0.76 | CYP17A1 (0.40) | LMNACYP3A4CA12CA1CA2 | |
| SCHEMBL27327312 | 0.76 | CYP17A1 (0.40) | LMNACYP3A4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090035267-A1 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008021733-A2 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021960-A2 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021871-A2 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008019289-A2 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008002924-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-0618209-B1 | Pyridothiadiazines, processes for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1998-12-23 | — | — | EP | disclosed |
| US-5459138-A | Dysfunctions of glutamatergic neurotransmission associated with learning and memory | ADIR ET COMPAGNIE (FR) | 1995-10-17 | — | — | US | disclosed |
| EP-0618209-A1 | Pyridothiadiazines, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035267-A1 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, HPN | LMNA 1556/4885HTT 4527/4885CYP3A4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.